Cangrelor tetrasodium
Based on 4 publication(s) in Google Scholar
Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.96%
- CAS No.: 163706-36-3
- 화학식: C17H21Cl2F3N5Na4O12P3S2
- 분자량:864.29
-
보관:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
HY-10064
TicagrelorP2Y12 Antagonist -
HY-B0606
Diquafosol tetrasodiumP2Y2 Receptor Agonist -
HY-15283
ClopidogrelAntiplatelet Agent -
HY-15284A
Prasugrel hydrochlorideP2Y12 Receptor Antagonist -
HY-W010918
Adenosine 5'-diphosphate -
HY-108660
PSB-0739P2Y12 Receptor Antagonist -
HY-B0089
AcarboseAlpha-Glucosidase Inhibitor -
HY-P0017
AprotininBPTI Inhibitor -
HY-108648
2-MeS-ADP trisodiumP2Y Receptor Agonist -
HY-50856
RuxolitinibJAK1/2 Inhibitor -
HY-15799
AZD1283P2Y12 Receptor Antagonist -
HY-N0148
RutinCBR1 Inhibitor
Publications Citing Use of MedChemExpress (MCE) Cangrelor tetrasodium
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
ELISA
-
WB
All P2Y Receptor Isoforms
More
Biological Activity
제품 설명
IC50 & Target
|
P2Y12 Receptor |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Platelet | IC50 |
0.4 nM
Compound: cangrelor
|
Inhibition of ADP-induced platelet aggregation in human platelet rich plasma
Inhibition of ADP-induced platelet aggregation in human platelet rich plasma
|
[PMID: 22531380] |
In Vitro
Cangrelor tetrasodium is the only potent intravenous direct and specific adenosine diphosphate (ADP) P2Y12 receptor antagonist[1].
?
Cangrelor tetrasodium has pKb of 8.6-9.2 for hP2Y12 receptor[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 163706-36-3
-
Appearance Solid
-
분자량 864.29
-
화학식 C17H21Cl2F3N5Na4O12P3S2
-
Color White to off-white
-
SMILES
O[C@H]1[C@@H](O)[C@H](N2C3=NC(SCCC(F)(F)F)=NC(NCCSC)=C3N=C2)O[C@@H]1COP(OP(C(Cl)(P(O[Na])(O[Na])=O)Cl)(O[Na])=O)(O[Na])=O
-
Synonyms
AR-C69931MX tetrasodium
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep
ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape in hepatocellular carcinoma. [Abstract]2024 Nov 9;43(11):114962. PMID: 39522165 -
Biochem Pharmacol
2025 Oct 23:117451. PMID: 41138926
Cangrelor tetrasodium purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Oct 23:117451. [Abstract]
Determination of Avibactam, Lopromide, Cangrelor tetrasodium, Protirelin, and Ioxilan IC50 values in Huh7 and Hep3B cells.
-
Int J Mol Sci
Discovery of TRPV4-Targeting Small Molecules with Anti-Influenza Effects Through Machine Learning and Experimental Validation. [Abstract]2025 Feb 6;26(3):1381. PMID: 39941149
Cangrelor tetrasodium purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Feb 6;26(3):1381. [Abstract]
Weight changes in mice infected with and treated with H1N1-UI182. The combined results of the two studies showed that treatment with glecaprevir, Cangrelor tetrasodium (Cangrelor), acarbose, and everolimus significantly slowed the rate of weight loss in virus-infected mice.
-
Mol Nutr Food Res
A Collagen-Derived Oligopeptide from Salmo salar Collagen Hydrolysates Restrains Atherogenesis in ApoE-/- Mice via Targeting P2 Y12 Receptor. [Abstract]2022 Jul;66(13):e2200166. PMID: 35490399
Cangrelor tetrasodium purchased from MedChemExpress. Usage Cited in: Mol Nutr Food Res. 2022 Jul;66(13):e2200166. [Abstract]
The EA. hy926 cells were pretreated with vehicle (M), OG-5 for 2 hours followed by stimulated with ADP for 4 hours, then the treated cells and supernatants were collected. The release of MCP-1 and VCAM-1 in supernatant were determined by ELISA kit and adhesion molecule ICAM-1 was determined in cell lysates. The results showed that treatment with OG-5 significantly inhibited the increase in ADP-induced MCP-1 and VCAM-1 production, showing a comparable effect with Cangrelor tetrasodium (0.5 µM) at the concentration of 0.5 mM.
Cangrelor tetrasodium purchased from MedChemExpress. Usage Cited in: Mol Nutr Food Res. 2022 Jul;66(13):e2200166. [Abstract]
Immunoblotting and densitometric analyses of p-VASP (Ser157). Platelets were preincubated with vehicle and different concentrations of OG-5 for 5 min at 37 ℃, in the presence or absence of the specific inhibitors and then stimulated with agonist. The reaction was stopped by addition of RIPA buffer immediately and the cell lysates were applied to immunoblot analysis with phospho-specific antibody. The results showed that Cangrelor tet (0.5 μM) attenuated the 2MeS-ADP-induced reduction in p-VASP(S157) levels.
용액&용해도
In Vitro:
H2O : 100 mg/mL (115.70 mM; Need ultrasonic)
DMSO : 12.5 mg/mL (14.46 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.25 mg/mL (1.45 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 1.25 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.25 mg/mL (1.45 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 1.25 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (115.70 mM); Clear solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
순도&문서
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Bhattad VB, , et al. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Ann Transl Med. 2019;7(17):408. [Content Brief]
[2]. Zhan T, Wei T, et al. Cangrelor alleviates bleomycin-induced pulmonary fibrosis by inhibiting platelet activation in mice. Mol Immunol. 2020;120:83-92. [Content Brief]
[3]. Bekő K, et al. Contribution of platelet P2Y12 receptors to chronic Complete Freund's adjuvant-induced inflammatory pain. J Thromb Haemost. 2017;15(6):1223-1235. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 1.1570 mL | 5.7851 mL | 11.5702 mL | 28.9255 mL |
| 5 mM | 0.2314 mL | 1.1570 mL | 2.3140 mL | 5.7851 mL | |
| 10 mM | 0.1157 mL | 0.5785 mL | 1.1570 mL | 2.8925 mL | |
| H2O | 15 mM | 0.0771 mL | 0.3857 mL | 0.7713 mL | 1.9284 mL |
| 20 mM | 0.0579 mL | 0.2893 mL | 0.5785 mL | 1.4463 mL | |
| 25 mM | 0.0463 mL | 0.2314 mL | 0.4628 mL | 1.1570 mL | |
| 30 mM | 0.0386 mL | 0.1928 mL | 0.3857 mL | 0.9642 mL | |
| 40 mM | 0.0289 mL | 0.1446 mL | 0.2893 mL | 0.7231 mL | |
| 50 mM | 0.0231 mL | 0.1157 mL | 0.2314 mL | 0.5785 mL | |
| 60 mM | 0.0193 mL | 0.0964 mL | 0.1928 mL | 0.4821 mL | |
| 80 mM | 0.0145 mL | 0.0723 mL | 0.1446 mL | 0.3616 mL | |
| 100 mM | 0.0116 mL | 0.0579 mL | 0.1157 mL | 0.2893 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Cangrelor tetrasodium Related Classifications
HY-19638A Related Classifications
Powered by Bioz